Update on papillary kidney cancer
The following is an interview with Dr Ramaprasad Srinivasan, Head of the [...]
Collaboration to develop a cancer therapy to be used with immune checkpoint inhibitors
Bristol-Myers Squibb and Nektar Therapeutics are working together to develop a cancer therapy [...]
Promising new immunotherapy drug for advanced/metastatic kidney cancer
Immunotherapy has revolutionised the treatment of renal cell carcinoma (RCC). [...]
Adjuvant sunitinib declined by European Medicines Agency committee
The Committee for Medicinal Products for Human Use (CHMP) of [...]
Combination therapies for kidney cancer
The following is a Practice Update interview with Dr Hans Hammers, Associate [...]
New insights into immune-related adverse events in genitourinary cancers
The following is an interview with Dr Tanya Dorff, Associate Clinical [...]
KCSN Trustee appointed as Cancer Research UK Senior Clinical Advisor in clinical research
Cancer Research UK announces the appointment of Dr James Larkin [...]
Potential role for high dose IL2 in metastatic kidney cancer
The following is an interview with Dr Tanya Dorff, Associate Clinical [...]
First-line immunotherapy for metastatic kidney cancer
The following is a Practice Update interview with Dr Eric [...]
Managing adverse events for cancer immunotherapies
Immunotherapy treatments for cancer hold great promise, but also come [...]
